MedTrace Logo

A Study for HSK44459 in Participants With Atopic Dermatitis

NCT06996912 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-01-02

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

HSK44459

HSK44459 will be administered orally twice daily

DRUG

Placebo

Placebo will be administered orally twice daily

Sponsors & Collaborators

  • Xizang Haisco Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2026-01-20
Completion
2026-03-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06996912 on ClinicalTrials.gov